Generate Biomedicines’ (GENB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Generate Biomedicines (NASDAQ:GENB) in a report released on Monday,Benzinga reports. The firm currently has a $30.00 target price on the stock.

Other research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Weiss Ratings raised Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.40.

Generate Biomedicines Stock Performance

Shares of NASDAQ GENB opened at $13.57 on Monday. The firm has a market capitalization of $1.74 billion and a P/E ratio of -8.53. Generate Biomedicines has a one year low of $11.00 and a one year high of $22.67. The company’s fifty day moving average is $15.56 and its two-hundred day moving average is $14.39.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. On average, sell-side analysts forecast that Generate Biomedicines will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Generate Biomedicines

Large investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new position in Generate Biomedicines during the second quarter worth about $196,000. AXQ Capital LP acquired a new stake in shares of Generate Biomedicines in the second quarter valued at approximately $218,000. Squarepoint Ops LLC purchased a new position in shares of Generate Biomedicines during the 2nd quarter worth approximately $530,000. Bank of New York Mellon Corp acquired a new position in shares of Generate Biomedicines during the 2nd quarter worth approximately $967,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Generate Biomedicines in the 2nd quarter valued at approximately $1,431,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.